Abstract
Background Previous models of Alzheimer’s disease (AD) progression were primarily hypothetical or based on data originating from single cohort studies. However, cohort datasets are subject to specific inclusion and exclusion criteria that influence the signals observed in their collected data. Furthermore, each study measures only a subset of AD relevant variables. To gain a comprehensive understanding of AD progression, the heterogeneity and robustness of estimated progression patterns must be understood, and complementary information contained in cohort datasets be leveraged.
Methods We compared ten event-based models that we fit to ten independent AD cohort datasets. Additionally, we designed and applied a novel rank aggregation algorithm that combines partially overlapping, individual event sequences into a meta-sequence containing the complementary information from each cohort.
Results We observed overall consistency across the ten event-based model sequences (Kendall’s tau correlation coefficient of 0.78±0.13), despite variance in the positioning of mainly imaging variables. The changes described in the aggregated meta-sequence are broadly consistent with current understanding of AD progression, starting with cerebrospinal fluid amyloid beta, followed by memory impairment, tauopathy, FDG-PET, and ultimately brain deterioration and impairment of visual memory.
Conclusion Overall, the event-based models demonstrated similar and robust disease cascades across independent AD cohorts. Aggregation of data-driven results can combine complementary strengths and information of patient-level datasets. Accordingly, the derived meta-sequence draws a more complete picture of AD pathology compared to models relying on single cohorts.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 826421, ‘TheVirtualBrain-Cloud’, and under grant agreement No. 666992 ‘EuroPOND’.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study involves only openly available human data, which can be obtained from: ADNI: The Alzheimer’s Disease Neuroimaging Initiative JADNI: Japanese Alzheimer’s Disease Neuroimaging Initiative AIBL: The Australian Imaging, Biomarker Lifestyle Flagship Study of Ageing NACC: The National Alzheimer’s Coordinating Center ANM: AddNeuroMed EMIF-1000: European Medical Information Framework EDSD: European DTI Study on Dementia ARWIBO: Alzheimer’s Disease Repository Without Borders OASIS: Open Access Series of Imaging Studies WMHAD: White Matter Hyperintensities in Alzheimer’s Disease
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵1 Alzheimer’s Disease Neuroimaging Initiative: Data used in the preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
↵2 Japanese Alzheimer’s Disease Neuroimaging Initiative: Data used in preparation of this article were obtained from the Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI) database deposited in the National Bioscience Database Center Human Database, Japan (Research ID: hum0043.v1, 2016). As such, the investigators within J-ADNI contributed to the design and implementation of J-ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of J-ADNI investigators can be found at: https://humandbs.biosciencedbc.jp/en/hum0043-j-adni-authors.
↵3 Data used in preparation of this article were obtained from the Alzheimer’s Disease Repository Without Borders (ARWiBo) database (www.arwibo.it). As such, the researchers within the ARWiBo contributed to the design and implementation of ARWiBo and/or provided data but did not participate in analysis or writing of this report. A complete listing of ARWiBo researchers can be found at: www.arwibo.it/acknowledgement.it
Data Availability
De-identified data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (https://adni.loni.usc.edu), the Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) database (https://aibl.csiro.au/), the European Collaboration for the Discovery of Novel Biomarkers for Alzheimer’s Disease (AddNeuroMed) (https://www.synapse.org/#!Synapse:syn4988768), Alzheimer’s Disease Repository Without Borders (ARWIBO) (https://www.neugrid2.eu/), Open Access Series of Imaging Studies (OASIS) (https://www.neugrid2.eu/), White Matter Hyperintensities in Alzheimer’s Disease (WMH-AD) (https://www.neugrid2.eu/), European Diffusion Tensor Imaging Study in Dementia (EDSD) (https://www.neugrid2.eu/), National Alzheimer’s Coordinating Center (NACC) (https://naccdata.org/), Japanese Alzheimer’s Disease Neuroimaging Initiative (JADNI) (https://humandbs.biosciencedbc.jp/en/hum0043-v1), European Medical Information Framework for Alzheimer’s Disease Multimodal Biomarker Discovery (EMIF-AD MBD) (https://emif-catalogue.eu; http://www.emif.eu/about/emif-ad).
List of abbreviations
- ADNI
- The Alzheimer’s Disease Neuroimaging Initiative
- JADNI
- Japanese Alzheimer’s Disease Neuroimaging Initiative
- AIBL
- The Australian Imaging, Biomarker Lifestyle Flagship Study of Ageing
- NACC
- The National Alzheimer’s Coordinating Center
- ANM
- AddNeuroMed
- EMIF-1000
- European Medical Information Framework
- EDSD
- European DTI Study on Dementia
- ARWIBO
- Alzheimer’s Disease Repository Without Borders
- OASIS
- Open Access Series of Imaging Studies
- WMHAD
- White Matter Hyperintensities in Alzheimer’s Disease
- CDRSB
- Clinical Dementia Rating Sum of Boxes
- NPI
- Neuropsychiatric Inventory
- LDEL
- Logical Memory - Delayed Recall Total Number of Story Units Recalled
- ADAS13
- Alzheimer’s Disease Assessment Scale (13-items)
- ADAS11
- Alzheimer’s Disease Assessment Scale (11-items)
- MMSE
- Mini-Mental State Examination
- LIMM
- Logical Memory - Immediate Recall Total Number of Story Units Recalled
- TRABS
- Trail Making Test-B
- DIGITS
- Digit-Symbol Coding Test
- LIDE
- California Verbal Learning Test Delayed Raw Score
- CATFLU
- Category Fluency (animals - fruits/vegetables)
- FIGC
- Figure Copy
- LIRE
- California Verbal Learning Test Recall Raw Score
- FIGR
- Figure recall
- STROOP
- C/D Stroop Test Raw
- STM
- Short Term Memory
- LANGU
- Language
- ORIENT
- Perceptual Orientation
- MENMA
- Mental Manipulation
- ATTEN
- Attention
- CLKS
- Clock Drawing Test Total Score
- EXECUTIVE
- Executive Memory
- LICOR
- Word List Learning Trial
- BNTS
- Boston Naming Test Score
- WAIS
- Digit Symbol Substitution Test
- ABETA
- Amyloid-β
- TAU
- Total Tau
- PTAU
- Phosphorylated Tau (p-Tau)
- ENTOR
- Entorhinal Volume
- HIPPO
- Hippocampal Volume
- FUSIF
- Fusiform Volume
- VENT
- Ventricles Volume
- MIDTEPM
- MiddleTemporal Volume
- CSFVOL
- Accumulated CSF in the Brain
- FDG
- Fluorodeoxyglucose Positron Emission Tomography (FDG PET)
- MRI
- Magnetic resonance imaging
- MCI
- Mild cognitive impairment
- AD
- Alzheimer’s disease
- CU
- Cognitive unimpairment
- KTC
- Kendall’s tau rank correlations
- EBM
- Event-based model
- CSF
- Cerebrospinal fluid
